Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis

Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis

Blog Article

ABSTRACTInflammatory bowel disease (IBD) is a chronic and recurrent condition affecting the gastrointestinal tract.Disturbed gut microbiota and abnormal bile acid (BA) metabolism are notable in IBD, suggesting a bidirectional relationship.Specifically, the diversity of the gut microbiota influences BA composition, whereas altered BA profiles can disrupt the microbiota.

IBD patients often exhibit increased primary Bokcase bile acid and reduced secondary bile acid concentrations due to a diminished bacteria population essential for BA metabolism.This imbalance activates BA receptors, undermining intestinal integrity and immune function.Consequently, targeting the microbiota-BA axis may rectify these disturbances, offering symptomatic relief in IBD.

Here, the interplay between gut microbiota and bile acids (BAs) is reviewed, with EYE LINE WARM BROWN #1415 a particular focus on the role of gut microbiota in mediating bile acid biotransformation, and contributions of the gut microbiota-BA axis to IBD pathology to unveil potential novel therapeutic avenues for IBD.